For those desiring to outshine the market, the strategic selection of individual stocks is paramount. Well-chosen stocks have the potential to substantially boost your wealth.
The closing price of Monte Rosa Therapeutics Inc (NASDAQ: GLUE) was $24.08 for the day, up 0.08% from the previous closing price of $24.06. In other words, the price has increased by $0.08 from its previous closing price. On the day, 1.24 million shares were traded. GLUE stock price reached its highest trading level at $24.46 during the session, while it also had its lowest trading level at $23.42.
Ratios:
Our analysis of GLUE’s different ratios will help us gain a deeper understanding of the company. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.69 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 12.66. For the most recent quarter (mrq), Quick Ratio is recorded 6.54 and its Current Ratio is at 6.54. In the meantime, Its Debt-to-Equity ratio is 0.16 whereas as Long-Term Debt/Eq ratio is at 0.15.
Upgrades & Downgrades
In the most recent recommendation for the company, Wells Fargo on December 19, 2024, Downgraded its rating to Equal Weight and sets its target price to $11 from $14 previously.
On February 15, 2024, Wedbush started tracking the stock assigning a Outperform rating and target price of $11.
Wells Fargo Upgraded its Equal Weight to Overweight on January 03, 2023, while the target price for the stock was maintained at $18.
Insider Transactions:
Also, insider trades can serve as a great indicator of what management thinks about the future direction of a stock’s price. A recent insider transaction in this stock occurred on Jan 07 ’26 when Warmuth Markus sold 5,466 shares for $23.49 per share. The transaction valued at 128,373 led to the insider holds 618,937 shares of the business.
Warmuth Markus bought 5,466 shares of GLUE for $128,372 on Jan 07 ’26. On Jan 05 ’26, another insider, Nickson Philip, who serves as the Chief Business & Legal Officer of the company, sold 3,155 shares for $15.17 each. As a result, the insider received 47,861 and left with 60,845 shares of the company.
Valuation Measures:
Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, GLUE now has a Market Capitalization of 1835925632 and an Enterprise Value of 1216945664. As of this moment, Monte’s Price-to-Earnings (P/E) ratio for their current fiscal year is 78.85. For the stock, the TTM Price-to-Sale (P/S) ratio is 10.11 while its Price-to-Book (P/B) ratio in mrq is 6.05. Its current Enterprise Value per Revenue stands at 6.704 whereas that against EBITDA is 72.265.
Stock Price History:
The Beta on a monthly basis for GLUE is 1.62, which has changed by 3.254642 over the last 52 weeks, in comparison to a change of 0.15507638 over the same period for the S&P500. Over the past 52 weeks, GLUE has reached a high of $25.77, while it has fallen to a 52-week low of $3.50. The 50-Day Moving Average of the stock is 44.23%, while the 200-Day Moving Average is calculated to be 184.57%.
Shares Statistics:
GLUE traded an average of 1.56M shares per day over the past three months and 4170250 shares per day over the past ten days. A total of 61.79M shares are outstanding, with a floating share count of 54.70M. Insiders hold about 28.25% of the company’s shares, while institutions hold 60.52% stake in the company. Shares short for GLUE as of 1767139200 were 8454052 with a Short Ratio of 5.43, compared to 1764288000 on 7006369. Therefore, it implies a Short% of Shares Outstanding of 8454052 and a Short% of Float of 16.91.
Earnings Estimates
. The current assessment of Monte Rosa Therapeutics Inc (GLUE) involves the perspectives of 7.0 analysts closely monitoring its market dynamics.The consensus estimate for the next quarter is -$0.48, with high estimates of -$0.32 and low estimates of -$0.59.
Analysts are recommending an EPS of between $0.04 and -$0.45 for the fiscal current year, implying an average EPS of -$0.21. EPS for the following year is -$1.38, with 7.0 analysts recommending between $0.25 and -$2.57.
Revenue Estimates
A total of 7 analysts have provided revenue estimates for GLUE’s current fiscal year. The highest revenue estimate was $160.9M, while the lowest revenue estimate was $121M, resulting in an average revenue estimate of $136.47M. In the same quarter a year ago, actual revenue was $75.62M
